HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Photorefractive keratectomy for compound myopic astigmatism.

AbstractPURPOSE:
To evaluate the safety and efficacy of photorefractive keratectomy for the treatment of primary compound myopic astigmatism.
METHODS:
In a prospective study, 93 eyes from 56 patients with a mean spherical equivalent of -4.98 +/- 1.80 diopters (range, -1.75 to -8.5) underwent photoastigmatic refractive keratectomy with the Summit Apex Plus excimer laser using erodible mask technology and were followed for 2 years. Primary outcome measures included an assessment of astigmatic correction through vector analysis, manifest refraction, uncorrected visual acuity, corneal clarity, and the presence of adverse symptoms.
RESULTS:
Eighty-five eyes (91.4%) were available for analysis at 6 months. Mean spherical equivalent refraction was reduced 85% (mean, -0.75 +/- 0.85 diopter) and the target-induced astigmatism was reduced 70% (mean, 0.98 +/- 1.88 diopters). Forty-eight eyes (56%) had an uncorrected visual acuity of 20/20 or greater, whereas 70 eyes (82%) had an uncorrected visual acuity of 20/40 or greater. Twenty-four eyes (26% ) required re-treatment because of undercorrection of the spherical equivalent and astigmatic components after the 6-month follow-up. Fifty-nine of the remaining eyes were available at the 24-month visit. Mean spherical equivalent refraction was reduced to -0.39 +/- 0.72 diopter (91.8%). The target-induced astigmatism was reduced 64% from 1.74 diopters. Forty-one eyes (81.3%) were within +/-1.0 diopter of attempted spherical equivalent correction. Stability within a spherical equivalent of +/-0.5 diopter occurred after the first postoperative month. Fifty-six eyes (94.9%) had an uncorrected visual acuity of 20/40 or greater, whereas 34 eyes (57.6 %) demonstrated an uncorrected visual acuity of 20/20 or greater. One eye (1.7%) lost 2 or more lines of best spectacle-corrected visual acuity.
CONCLUSION:
Photoastigmatic refractive keratectomy with the Summit Apex Plus excimer laser is a safe and effective method of reducing compound myopic astigmatism. However, higher re-treatment rates may result from significant undercorrections because of current laser algorithms and variability in the mean angle of error.
AuthorsW W Haw, E E Manche
JournalAmerican journal of ophthalmology (Am J Ophthalmol) Vol. 130 Issue 1 Pg. 12-9 (Jul 2000) ISSN: 0002-9394 [Print] United States
PMID11004254 (Publication Type: Clinical Trial, Clinical Trial, Phase III, Controlled Clinical Trial, Journal Article)
Topics
  • Adult
  • Astigmatism (surgery)
  • Cornea (surgery)
  • Female
  • Follow-Up Studies
  • Humans
  • Lasers, Excimer
  • Male
  • Middle Aged
  • Myopia (surgery)
  • Photorefractive Keratectomy
  • Postoperative Complications
  • Prospective Studies
  • Refraction, Ocular
  • Reoperation
  • Safety
  • Treatment Outcome
  • Visual Acuity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: